Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endoscopic Mucosal Resection | 16 | 2025 | 79 | 3.350 |
Why?
|
| Capsule Endoscopy | 5 | 2021 | 20 | 1.710 |
Why?
|
| Gastrointestinal Hemorrhage | 5 | 2021 | 237 | 1.340 |
Why?
|
| Colonic Polyps | 4 | 2025 | 85 | 1.190 |
Why?
|
| Esophageal Neoplasms | 6 | 2024 | 386 | 1.030 |
Why?
|
| Endoscopy, Gastrointestinal | 3 | 2024 | 240 | 0.940 |
Why?
|
| Colonoscopy | 6 | 2025 | 252 | 0.940 |
Why?
|
| Myotomy | 5 | 2025 | 21 | 0.920 |
Why?
|
| Wound Closure Techniques | 1 | 2025 | 27 | 0.920 |
Why?
|
| Suture Techniques | 1 | 2025 | 190 | 0.840 |
Why?
|
| Colorectal Neoplasms | 6 | 2025 | 632 | 0.800 |
Why?
|
| Academic Medical Centers | 1 | 2024 | 333 | 0.770 |
Why?
|
| Colon | 2 | 2022 | 370 | 0.730 |
Why?
|
| Feasibility Studies | 1 | 2024 | 822 | 0.700 |
Why?
|
| Intestinal Diseases | 1 | 2021 | 76 | 0.650 |
Why?
|
| Pancreatic Cyst | 1 | 2019 | 28 | 0.610 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2019 | 34 | 0.600 |
Why?
|
| Hematemesis | 1 | 2018 | 6 | 0.590 |
Why?
|
| Pancreas | 1 | 2019 | 222 | 0.580 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 298 | 0.570 |
Why?
|
| Endoscopy, Digestive System | 2 | 2018 | 157 | 0.570 |
Why?
|
| Pancreatitis | 1 | 2019 | 140 | 0.560 |
Why?
|
| Pancreatic Neoplasms | 2 | 2024 | 728 | 0.540 |
Why?
|
| Delayed Diagnosis | 1 | 2018 | 133 | 0.520 |
Why?
|
| Neoplasm, Residual | 4 | 2025 | 136 | 0.510 |
Why?
|
| Operative Time | 4 | 2025 | 192 | 0.510 |
Why?
|
| Natural Orifice Endoscopic Surgery | 4 | 2025 | 72 | 0.480 |
Why?
|
| Aged | 20 | 2025 | 21415 | 0.460 |
Why?
|
| Esophageal Motility Disorders | 2 | 2025 | 22 | 0.440 |
Why?
|
| Prospective Studies | 10 | 2025 | 6569 | 0.440 |
Why?
|
| Treatment Outcome | 18 | 2025 | 13019 | 0.430 |
Why?
|
| Esophageal Achalasia | 2 | 2025 | 46 | 0.420 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2019 | 767 | 0.400 |
Why?
|
| Middle Aged | 20 | 2025 | 28976 | 0.380 |
Why?
|
| Adenocarcinoma | 3 | 2024 | 1015 | 0.340 |
Why?
|
| Humans | 37 | 2025 | 131985 | 0.340 |
Why?
|
| Cost-Benefit Analysis | 2 | 2025 | 576 | 0.330 |
Why?
|
| Male | 24 | 2025 | 64910 | 0.320 |
Why?
|
| Gastroenterology | 2 | 2024 | 211 | 0.310 |
Why?
|
| Esophagoscopy | 3 | 2025 | 168 | 0.310 |
Why?
|
| Aged, 80 and over | 8 | 2025 | 7100 | 0.300 |
Why?
|
| Surgical Instruments | 2 | 2025 | 57 | 0.280 |
Why?
|
| Gastrointestinal Tract | 2 | 2021 | 232 | 0.270 |
Why?
|
| Barrett Esophagus | 2 | 2021 | 355 | 0.260 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2024 | 86 | 0.260 |
Why?
|
| Retrospective Studies | 16 | 2025 | 17391 | 0.250 |
Why?
|
| Female | 21 | 2025 | 70623 | 0.250 |
Why?
|
| Propensity Score | 2 | 2025 | 257 | 0.240 |
Why?
|
| Duodenoscopy | 1 | 2025 | 17 | 0.240 |
Why?
|
| Duodenal Neoplasms | 1 | 2025 | 26 | 0.230 |
Why?
|
| Neuroendocrine Tumors | 1 | 2025 | 58 | 0.220 |
Why?
|
| Gastroenterologists | 1 | 2024 | 12 | 0.220 |
Why?
|
| Intestinal Polyps | 1 | 2024 | 29 | 0.220 |
Why?
|
| Electrosurgery | 1 | 2024 | 17 | 0.220 |
Why?
|
| Standard of Care | 3 | 2019 | 134 | 0.220 |
Why?
|
| Gels | 1 | 2024 | 72 | 0.210 |
Why?
|
| Esophageal Stenosis | 1 | 2024 | 46 | 0.210 |
Why?
|
| Adenoma | 1 | 2025 | 146 | 0.210 |
Why?
|
| Fundoplication | 1 | 2024 | 70 | 0.210 |
Why?
|
| Salvage Therapy | 1 | 2025 | 200 | 0.200 |
Why?
|
| Oncolytic Viruses | 1 | 2024 | 76 | 0.200 |
Why?
|
| Tertiary Care Centers | 1 | 2024 | 256 | 0.200 |
Why?
|
| Aftercare | 1 | 2024 | 155 | 0.200 |
Why?
|
| Mentoring | 1 | 2024 | 81 | 0.200 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2023 | 88 | 0.190 |
Why?
|
| Equipment Design | 1 | 2024 | 602 | 0.190 |
Why?
|
| Anemia | 2 | 2024 | 350 | 0.190 |
Why?
|
| Postoperative Care | 1 | 2024 | 312 | 0.190 |
Why?
|
| Colonic Neoplasms | 1 | 2025 | 262 | 0.190 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 233 | 0.190 |
Why?
|
| Gastroesophageal Reflux | 1 | 2024 | 338 | 0.170 |
Why?
|
| Cytodiagnosis | 1 | 2020 | 20 | 0.170 |
Why?
|
| Bile Ducts | 1 | 2020 | 54 | 0.160 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2020 | 81 | 0.160 |
Why?
|
| Equivalence Trials as Topic | 1 | 2019 | 24 | 0.160 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2019 | 31 | 0.150 |
Why?
|
| Costs and Cost Analysis | 1 | 2019 | 166 | 0.150 |
Why?
|
| Bile Duct Neoplasms | 1 | 2020 | 122 | 0.150 |
Why?
|
| Endosonography | 1 | 2019 | 82 | 0.150 |
Why?
|
| Intestine, Small | 1 | 2021 | 309 | 0.150 |
Why?
|
| Unnecessary Procedures | 1 | 2018 | 60 | 0.140 |
Why?
|
| Diabetes Complications | 1 | 2019 | 207 | 0.140 |
Why?
|
| Adult | 7 | 2025 | 31547 | 0.140 |
Why?
|
| Postoperative Complications | 3 | 2025 | 3142 | 0.140 |
Why?
|
| Inulin | 1 | 2016 | 18 | 0.130 |
Why?
|
| Cystic Fibrosis | 1 | 2019 | 264 | 0.130 |
Why?
|
| Fatty Acids, Volatile | 1 | 2016 | 46 | 0.120 |
Why?
|
| Acute Disease | 1 | 2019 | 1160 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2025 | 1304 | 0.120 |
Why?
|
| Epithelial Cells | 1 | 2019 | 903 | 0.110 |
Why?
|
| Quality of Life | 1 | 2024 | 2158 | 0.100 |
Why?
|
| Length of Stay | 1 | 2019 | 1380 | 0.100 |
Why?
|
| United States | 4 | 2025 | 11653 | 0.100 |
Why?
|
| Obesity | 1 | 2025 | 2394 | 0.100 |
Why?
|
| Time Factors | 2 | 2018 | 6443 | 0.090 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 923 | 0.090 |
Why?
|
| Young Adult | 2 | 2020 | 9952 | 0.070 |
Why?
|
| Risk Factors | 2 | 2024 | 10941 | 0.070 |
Why?
|
| Intestinal Mucosa | 2 | 2023 | 794 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 3830 | 0.070 |
Why?
|
| Esophageal Spasm, Diffuse | 1 | 2025 | 3 | 0.060 |
Why?
|
| Duodenum | 1 | 2025 | 113 | 0.060 |
Why?
|
| Margins of Excision | 1 | 2024 | 57 | 0.050 |
Why?
|
| Albumins | 1 | 2024 | 95 | 0.050 |
Why?
|
| North America | 1 | 2024 | 265 | 0.050 |
Why?
|
| Esophageal Sphincter, Lower | 1 | 2023 | 13 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2024 | 140 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2024 | 240 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2024 | 311 | 0.050 |
Why?
|
| Rectum | 1 | 2023 | 114 | 0.050 |
Why?
|
| Sutures | 1 | 2022 | 69 | 0.050 |
Why?
|
| Brazil | 1 | 2022 | 140 | 0.050 |
Why?
|
| Consensus | 1 | 2024 | 649 | 0.040 |
Why?
|
| Gastric Mucosa | 1 | 2024 | 491 | 0.040 |
Why?
|
| Proton Pump Inhibitors | 1 | 2024 | 282 | 0.040 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2020 | 23 | 0.040 |
Why?
|
| Opioid-Related Disorders | 1 | 2024 | 285 | 0.040 |
Why?
|
| Peptides | 1 | 2024 | 846 | 0.040 |
Why?
|
| Learning Curve | 1 | 2020 | 57 | 0.040 |
Why?
|
| Canada | 1 | 2021 | 337 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2021 | 334 | 0.040 |
Why?
|
| Professional Practice | 1 | 2019 | 41 | 0.040 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2020 | 73 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2024 | 1441 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 2020 | 235 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2023 | 519 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 685 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2024 | 719 | 0.040 |
Why?
|
| Cholangiocarcinoma | 1 | 2020 | 122 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 471 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2025 | 1696 | 0.040 |
Why?
|
| Melena | 1 | 2018 | 5 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 294 | 0.040 |
Why?
|
| Stomach Neoplasms | 1 | 2024 | 565 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2018 | 195 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1342 | 0.030 |
Why?
|
| Propionates | 1 | 2016 | 33 | 0.030 |
Why?
|
| Biopsy | 1 | 2020 | 1284 | 0.030 |
Why?
|
| Esters | 1 | 2016 | 35 | 0.030 |
Why?
|
| Self Report | 1 | 2019 | 549 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 3011 | 0.030 |
Why?
|
| Fermentation | 1 | 2016 | 69 | 0.030 |
Why?
|
| Hospitalization | 1 | 2025 | 1898 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 1132 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 2140 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 329 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 1439 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 1458 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 3991 | 0.030 |
Why?
|
| Eating | 1 | 2016 | 381 | 0.030 |
Why?
|
| Energy Intake | 1 | 2016 | 493 | 0.030 |
Why?
|
| Logistic Models | 1 | 2018 | 1839 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2020 | 1068 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2022 | 5166 | 0.020 |
Why?
|
| Feces | 1 | 2016 | 755 | 0.020 |
Why?
|
| Adolescent | 1 | 2020 | 20535 | 0.010 |
Why?
|
| Child | 1 | 2020 | 25762 | 0.010 |
Why?
|